PHARMACEUTICAL COMPOSITION CONTAINING ATPIF1 FOR TREATMENT OF DIABETES

• US 20200129581A1
• Filed: 03/13/2018
• Published: 04/30/2020
• Est. Priority Date: 03/17/2017
• Status: Active Grant

• Current Assignee: Medi&Gene Incorporated
• Original Assignee: Korea University Research and Business Foundation
• Inventors: KIM, Hyeon Soo
• Granted Patent: US 10,946,060 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/005 Enzyme inhibitors protease inhibitors A61K38/55
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a pharmaceutical composition containing ATPase inhibitor factor 1 (ATPIF1) as an active ingredient for the prevention or treatment of diabetes or diabetic complications, and to a pharmaceutical composition containing ATP1F1 as an active ingredient for prevention or treatment of obesity. The composition containing ATPIF1, according to the present invention, has a diabetes treatment effect by promoting sugar absorption in muscle cells and improving insulin sensitivity, and has an obesity prevention or treatment effect by effects of suppressing fat synthesis in fat cells and promoting the browning of fat cells.

Claims

1. A method for preventing or treating diabetes or diabetic complications, comprising administering ATPIF1 (ATPase inhibitor factor 1).

2. The method according to claim 1, wherein the diabetes is type 1 diabetes or initial type 2 diabetes.

3. The method according to claim 1, wherein the diabetes complications comprise at least one selected from diabetic nephropathy, diabetic retinopathy, hyperlipidemia and fatty liver.

4. The method according to claim 1, wherein the ATPIF1 (ATPase inhibitor factor 1) promotes insulin sensitivity.

5. The method according to claim 1, further comprising administering insulin or an insulin analog.

6. A method for preventing or treating obesity, comprising administering ATPIF 1 (ATPase inhibitor factor 1).